Overview

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)